DAYBREAK: visual acuity, durability and the limits of GLOW extrapolation

Biology / Target

DAYBREAK evaluates parallel investigational arms of Zenkuda and KSI-501 against aflibercept in wet AMD. Zenkuda is an anti-VEGF therapy; KSI-501 adds IL-6 targeting. The shared trial does not make these the same molecule or the same hypothesis. [1] [2]

The clinical aim is to preserve visual benefit while reducing injection burden. Drying retinal fluid supports disease control, but an anatomical improvement cannot replace the visual-acuity endpoint. A patient may have less fluid without a commensurate functional gain.

Molecule / Exposure and treatment interval

Zenkuda dosing in DAYBREAK is individualized every 4–24 weeks after four monthly loading doses. The possibility of 24-week dosing is not the proportion of patients who actually sustain that interval. [1]

Durability must be measured alongside rescue injections, interval shortening and timing of endpoint assessment relative to the last dose. A favorable average injection count may conceal a subgroup requiring frequent retreatment. The dosing algorithm is part of the tested treatment strategy.

Prior clinical evidence: GLOW2 is a different indication

GLOW2 enrolled 255 diabetic-retinopathy patients, with 130 Zenkuda and 125 sham participants represented in the pipeline data. It tested DRSS improvement, not the wet-AMD BCVA noninferiority question. [2] [3]

This evidence supports activity and exposure duration in its own population. It cannot prove that DAYBREAK meets its margin versus an effective active comparator. Sham superiority and active-control noninferiority have different evidentiary burdens.

DAYBREAK design / Statistics

The August update guided September 2026 for the one-year primary readout. The trial has two investigational arms and an active comparator. Exact DAYBREAK randomized arm counts, the noninferiority margin and the complete statistical hierarchy have not been verified in the sources extracted here. [1]

Noninferiority is established by the confidence bound relative to a prespecified margin, not merely by the absence of a statistically significant difference. A failed superiority test cannot be relabeled as noninferiority. The margin must be clinically and historically justified.

Examine both intention-to-treat and protocol-adherent sensitivity analyses because missing data, rescue and nonadherence can make groups look artificially similar. Check each molecule separately; one successful arm does not establish the other.

A persuasive outcome combines an acceptable visual-acuity contrast with meaningful interval extension and manageable ocular safety. A favorable acuity result achieved only through frequent rescue would support a different clinical proposition than sustained benefit on long intervals.

Ocular safety and formulation history

GLOW2 reported no intraocular inflammation or retinal vasculitis; cataract rates were 2.3% with Zenkuda and 1.6% with sham. This is evidence from GLOW2, not a guarantee of the same safety in DAYBREAK. [2]

Inflammation, occlusive events, endophthalmitis, pressure change and vision loss should be separated by severity, timing and attribution. Different formulations, populations and repeated exposure can alter safety. A pooled low event rate may obscure a clinically important severe category.

Capital structure / Management

This report does not independently verify a current fully diluted capitalization. The immediate execution issue is transparent reporting of both DAYBREAK molecules, all injection exposure and the complete ocular event table rather than only a primary-endpoint headline.

Keep DAYBREAK and PEAK separate: they investigate different clinical settings and cannot serve as interchangeable confirmatory studies. Success in one program can motivate further development without statistically validating the other program.

September 27 verification / Confirmed presentation date

On September 25, Kodiak scheduled its DAYBREAK topline presentation for September 28, 2026, with a webcast at 08:30 Eastern Time. This replaces the previous September window with a confirmed presentation date. As of this verification, it is a scheduled disclosure, not an observed efficacy result. [4]

The earlier evidence and prospective interpretation below remain historical analyses. Evaluate tarcocimab and tabirafusp separately against the protocol-defined comparators, with exact arm counts, primary-endpoint confidence intervals, rescue-treatment rules and ocular safety. A presentation announcement does not resolve those clinical questions.

September 28, 2026 / DAYBREAK results replace the prospective readout

Kodiak disclosed the one-year DAYBREAK results on September 28, followed by its scheduled webcast. Both tarcocimab tedromer (Zenkuda) and tabirafusp alfa tedromer (KSI-501) met their separate visual-acuity noninferiority comparisons against aflibercept. This is an observed Phase 3 clinical readout, not a BLA submission or regulatory approval. The earlier sections and September 27 scheduling note remain the original pre-readout evidence; the dated sections here append the actual results without replacing those historical analyses. [5] [6] [7]

The principal change to the earlier interpretation is that the vision margin and observed safety denominators are now disclosed. The results support visual-acuity preservation relative to the prespecified margin, with longer dosing intervals for many tarcocimab recipients. They do not demonstrate superior vision, prove that IL-6 blockade adds clinical benefit, or validate KSI-101 in inflammatory macular edema. Kodiak still described a fourth-quarter 2026 multi-indication tarcocimab BLA as a plan.

DAYBREAK / Population, treatment and analysis sets

NCT06556368 is a randomized, parallel, masked Phase 3 study with planned 1:1:1 allocation. The registry snapshot last posted April 29, 2026 lists an estimated 675 participants, not actual enrollment. Eligible participants were at least 50 years old with active treatment-naïve neovascular AMD and study-eye BCVA of 25–78 ETDRS letters. Central fibrosis or atrophy, or fibrosis/atrophy exceeding half the lesion, and a non-study eye with hand-motion vision or worse were exclusions. These criteria limit extrapolation to heavily pretreated disease and advanced central scarring. [6] [8]

The presentation reports treated/safety populations of 220, 223 and 224, totaling 667. It does not establish actual randomized counts or a complete disposition by arm. The eight-person difference from the estimated registry enrollment must not be called dropout. The public registry summarizes BCVA change at Week 48, whereas the presentation defines the primary analysis as the average of Weeks 40, 44 and 48. Preserve that version distinction: an observed Week 48 mean is not the repeated-measures primary estimate.

Both experimental regimens began with four monthly injections. Subsequent disease-activity assessment used retinal fluid detected by an AI-assisted volumetric OCT tool. Tarcocimab could be repeated every 4–24 weeks; tabirafusp used scheduled every-eight-week treatment plus additional individualized monthly treatment. Aflibercept followed three monthly loading injections and every-eight-week dosing. This comparison combines molecule and regimen effects. A full protocol/SAP, estimand, missingness assumptions, rescue restrictions, discontinuation disposition and per-protocol sensitivity results were not recovered; the MMRM label alone does not resolve those issues.

DAYBREAK / Separate noninferiority estimates

The prespecified vision noninferiority margin was 4.5 ETDRS letters. Each reported confidence interval excludes a loss of 4.5 letters, but both include zero; neither comparison demonstrates superior vision. Preserve the source’s 95.02% confidence level rather than rounding it to 95%. The presentation calls the two pivotal comparisons independent at full alpha. Without the full SAP, this statement does not establish all secondary-endpoint multiplicity rules. [6]

The shared aflibercept arm has different adjusted means in the two pairwise MMRM comparisons: 6.9 and 6.6 letters, and −133.5 and −138.8 µm for central subfield thickness. These are source-reported model estimates, not separate control cohorts. They should not be averaged, silently reconciled, or subtracted across models. The OCT tests use a 75-µm noninferiority margin. The tarcocimab OCT p-value is explicitly nominal and not prespecified for hypothesis testing; neither OCT p-value proves greater drying than aflibercept.

DAYBREAK / Interval distribution is a selected-population result

The dosing-interval analysis includes 210 tarcocimab recipients with any completed visit on or after Week 36, rather than all 220 treated recipients. At the primary endpoint, 54% had a 24-week interval and 62% a 20- or 24-week interval. These are rounded proportions, not exact responder counts; 54% of 210 must not be converted into an invented integer numerator. The presentation also says 48% reached six-month dosing immediately after loading, but the analysis definition should not be assumed identical without further documentation. [6]

This supports the feasibility of long intervals under the study’s monitoring and retreatment algorithm. It is not a randomized demonstration that every patient needs fewer visits or that a 24-week interval will persist beyond the first year. The comparator’s fixed dosing schedule and the selected durability population preclude a like-for-like percentage comparison. The table and chart therefore show only the disclosed tarcocimab distribution.

DAYBREAK / Study-eye safety through Week 48

The disclosed tables concern investigator-reported study-eye events in treated safety populations. Their window is from first study drug through 28 days after the last dose, with the summary presented through Week 48. The table labels participants with at least one event separately from individual event terms; categories overlap and must not be added to obtain unique patients. These ocular summaries are not complete systemic TEAE or SAE totals. Deaths and all-cause discontinuation were not provided in the extracted tables and must not be recorded as zero. [6]

No intraocular inflammation was reported among the 220 tarcocimab recipients, versus one of 223 tabirafusp recipients and none of 224 controls. That observed zero does not establish absence of rare inflammatory risk. The study-eye cataract counts were one, zero and two, respectively. These new DAYBREAK observations do not overwrite the earlier GLOW2 cataract percentages: populations, formulations and exposure must remain identifiable by study and version.

Sources / References

1. Kodiak · DAYBREAK and PEAK study update · August 2026 SEC exhibit
2. Kodiak · GLOW2 topline results · March 26, 2026
3. Kodiak · Pipeline and clinical study data
4. Kodiak September 25, 2026: DAYBREAK topline presentation scheduled September 28
5. Kodiak · DAYBREAK result announcement · September 28, 2026, 06:30 EDT
6. Kodiak · DAYBREAK webcast presentation · September 28, 2026 · slides 9, 13–17, 21–24
7. Kodiak · SEC Form 8-K · September 28, 2026
8. ClinicalTrials.gov · NCT06556368 · posted April 29, 2026; retrieved September 30